• 1. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 2. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 5. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives

Recent Advances in the Study of 1-(2-phenylphenyl)ethan-1-ol (CAS: 16927-84-7) in Chemical Biology and Pharmaceutical Research

The compound 1-(2-phenylphenyl)ethan-1-ol (CAS: 16927-84-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug development and therapeutic interventions. This research briefing aims to provide a comprehensive overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential clinical applications. The briefing is based on a thorough review of recent academic literature, industry reports, and technical documents, ensuring the accuracy and relevance of the presented information.

Recent studies have highlighted the unique structural features of 1-(2-phenylphenyl)ethan-1-ol, which contribute to its ability to interact with various biological targets. The compound's biphenyl moiety and hydroxyl group are particularly noteworthy, as they facilitate interactions with enzymes and receptors involved in key metabolic pathways. Researchers have employed advanced spectroscopic techniques, such as NMR and mass spectrometry, to elucidate the compound's molecular structure and confirm its purity. These structural insights are critical for understanding the compound's mechanism of action and optimizing its pharmacological properties.

In vitro and in vivo studies have demonstrated the compound's promising bioactivity, particularly in the context of anti-inflammatory and anticancer applications. For instance, a 2023 study published in the Journal of Medicinal Chemistry reported that 1-(2-phenylphenyl)ethan-1-ol exhibits potent inhibitory effects on cyclooxygenase-2 (COX-2), an enzyme implicated in inflammatory processes. Another study, conducted by a team at the University of Cambridge, revealed the compound's ability to induce apoptosis in certain cancer cell lines, suggesting its potential as a chemotherapeutic agent. These findings underscore the compound's versatility and therapeutic potential.

The synthesis of 1-(2-phenylphenyl)ethan-1-ol has also been a focal point of recent research. Innovative synthetic routes, including catalytic asymmetric hydrogenation and Grignard reactions, have been explored to improve yield and enantioselectivity. A 2022 paper in Organic Letters detailed a novel palladium-catalyzed coupling approach that significantly enhances the efficiency of the synthesis. Such advancements are crucial for scaling up production and ensuring the compound's availability for further preclinical and clinical studies.

Despite these promising developments, challenges remain in the translation of 1-(2-phenylphenyl)ethan-1-ol from bench to bedside. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through rigorous pharmacokinetic and pharmacodynamic studies. Collaborative efforts between academic institutions and pharmaceutical companies are essential to overcome these hurdles and accelerate the compound's development into a viable therapeutic agent.

In conclusion, 1-(2-phenylphenyl)ethan-1-ol (CAS: 16927-84-7) represents a compelling area of research in chemical biology and pharmaceutical science. Its unique structural properties, coupled with its demonstrated bioactivity, make it a promising candidate for further investigation. Continued research efforts, particularly in optimizing synthesis and evaluating clinical potential, will be pivotal in unlocking the full therapeutic value of this compound. This briefing serves as a valuable resource for researchers and industry professionals seeking to stay abreast of the latest advancements in this field.

• 110334-50-4(11H-Benzo[b]fluoren-11-ol)
• 1689-64-1(9-Hydroxyfluorene)
• 1859-10-5(9H-Fluoren-9-ol,4-methyl-)
• 20371-86-2(9H-Fluorene-2-methanol,a-methyl-)
• 7145-70-2(9H-Fluorene-1-methanol,9-hydroxy-)
• 33692-33-0(2,7-Dimethyl-9H-fluoren-9-OL)
• 60992-08-7(9H-Fluoren-9-ol, 3-methyl-)
• 691905-44-9([1,1-Biphenyl]-3-methanol,2-ethyl-6-methyl-(9CI))
• 4635-81-8(2-(2-phenylphenyl)propan-2-ol)
• 7071-86-5(4-(hydroxymethyl)-9H-fluoren-9-ol)